

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Modern Chinese Medicine Group Co., Ltd.**

**現代中藥集團有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1643)**

### **APPOINTMENT OF JOINT COMPANY SECRETARY WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES**

#### **APPOINTMENT OF JOINT COMPANY SECRETARY**

The board of directors (the “**Board**” and the “**Directors**” respectively) of Modern Chinese Medicine Group Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that Ms Jia Yanru (賈豔茹) (“**Ms Jia**”) has been appointed as a joint company secretary of the Company with effect from 30 August 2023. The existing company secretary of the Company, namely Ms Chan Wan Ling Sammi (“**Ms Chan**”), will become the other Joint Company Secretary with effect from the same day and assist Ms Jia in discharging her duties as a joint company secretary of the Company.

The biographical details of Ms Jia are set out as follows:

Ms Jia, aged 40, was appointed as deputy general manager (finance) of the Company (“**Deputy GM**”) in August 2021. She is responsible for the management of financial, supervisory and compliance as well as investor relation matters and possesses experience in financial management in pharmaceutical industry for more than 20 years. Ms Jia joined the Group in 2004 and prior to being promoted as Deputy GM, Ms Jia was a finance manager of the Group.

Ms. Jia graduated from the Northeast Normal University (東北師範大學), the Mainland China with a Higher Education Graduation Certificate (major in accounting) (高等教育畢業證書 (會計專業)).

**WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE RULES (THE “LISTING RULES”) GOVERNING THE LISTING OF SECURITIES ON THE STOCK EXCHANGE OF HONG KONG LIMITED (THE “STOCK EXCHANGE”)**

The Company has applied to the Stock Exchange and has already been granted with a waiver (the “**Waiver**”) by the Stock Exchange from strict compliance with the requirements under Rules 3.28 and 8.17 of the Listing Rules) , which is valid for a period of three years from the appointment of Ms Jia as a joint company secretary (the “**Waiver Period**”), i.e. the Waiver Period commences on the date of this announcement.

The conditions under which the Stock Exchange granted the Waiver are: (i) Ms Jia must be assisted by Ms Chan, the other joint company secretary of the Company during the Waiver Period; and (ii) the Waiver could be revoked if there are material breaches of the Listing Rules by the Company. Before the end of the Waiver Period, the Company must demonstrate and seek the Stock Exchange’s confirmation that Ms Jia, having had the benefit of Ms Chan’s assistance during the Waiver Period, has attained the relevant experience and is capable of discharging the functions of company secretary under Rule 3.28 of the Listing Rules such that a further waiver will not be necessary. The Stock Exchange may withdraw or change the Waiver if the Company’s situation changes.

Despite the fact that Ms Chan is qualified under the Listing Rules, it is essential and efficient for the Company to appoint a person who is familiar with the operation and affairs of the Group as the company secretary of the Company. Ms Jia has been working in the Group for more than 19 years, she is familiar with the Group’s operation and affairs as well as the operation of the Board, who can immediately provide her preliminary advice and suggestions. Besides, as Ms Jia and all the executive Directors are stationed in the same office, they can communicate with each other without unnecessary delay. The Company believes that the joint company secretary arrangement will provide assistance to Ms Jia in accumulating the relevant experience at an early stage. Together with the relevant professional trainings to be taken by Ms Jia during the Waiver Period, it is likely that Ms Jia will satisfy the requirements under Note 2 to Rule 3.28 of the Listing Rules after the Waiver Period.

In view of the above, the Board believes that the joint company secretary arrangement is in the interest of the Company and that Ms Jia is suitable to act as a joint company secretary of the Company.

The biographical details of Ms Chan are as follows:

Ms Chan is a practising solicitor admitted in the Hong Kong Special Administrative Region and a member of the Law Society of Hong Kong. She has also been a Certified Management Accountant since 2016 and a Lawyer of the Supreme Court of New South Wales since 2014. Ms Chan has a Postgraduate Certificate in Laws and a Bachelor of Laws degree from the City University of Hong Kong and a Bachelor of Business Administration in Accounting and Finance degree from the University of Hong Kong.

The Board would like to extend its welcome to Ms Jia on her appointment.

By Order of the Board  
**Modern Chinese Medicine Group Co., Ltd.**  
**Zhang Hongli**  
*Executive Director*

Hong Kong, 30 August 2023

*As at the date of this announcement, the Board comprises three executive Directors, namely Ms. Zhang Hongli, Mr. Li Jinglian and Mr. Jiang Zhendong; and three independent non-executive Directors, namely Ms. Liu Ling, Mr. Leung Tsz Wing and Mr. Wong Chi Kin.*